Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
